Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Bellicum Pharmaceuticals, Inc (BLCM) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Bellicum Pharmaceuticals, Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1358403.
Total stock buying since 2015: $2,145,195.
Total stock sales since 2015: $18,409,405.
Total stock option exercises since 2015: $580,797.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 0 | $0 | 0 | $0 | 404,215 | $0 |
| 2022 | 0 | $0 | 0 | $0 | 337,709 | $0 |
| 2020 | 5,000 | $20,000 | 0 | $0 | 9,095 | $0 |
| 2019 | 68,000 | $79,604 | 0 | $0 | 15,812 | $0 |
| 2018 | 10,000 | $45,599 | 937,428 | $7,649,680 | 6,564 | $0 |
| 2017 | 166,666 | $1,999,992 | 83,894 | $964,578 | 13,823 | $35,248 |
| 2016 | 0 | $0 | 384,300 | $6,477,228 | 90,000 | $303,299 |
| 2015 | 0 | $0 | 161,800 | $3,317,919 | 95,000 | $242,250 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-01 | 0 | $0 | 0 | $0 | 404,215 | $0 |
| 2022-09 | 0 | $0 | 0 | $0 | 220,633 | $0 |
| 2022-01 | 0 | $0 | 0 | $0 | 117,076 | $0 |
| 2020-03 | 5,000 | $20,000 | 0 | $0 | 0 | $0 |
| 2020-01 | 0 | $0 | 0 | $0 | 9,095 | $0 |
| 2019-11 | 0 | $0 | 0 | $0 | 3,750 | $0 |
| 2019-09 | 40,000 | $50,000 | 0 | $0 | 0 | $0 |
| 2019-08 | 28,000 | $29,604 | 0 | $0 | 0 | $0 |
| 2019-01 | 0 | $0 | 0 | $0 | 12,062 | $0 |
| 2018-11 | 10,000 | $45,599 | 0 | $0 | 0 | $0 |
| 2018-09 | 0 | $0 | 10,000 | $70,410 | 0 | $0 |
| 2018-07 | 0 | $0 | 40,000 | $305,120 | 0 | $0 |
| 2018-05 | 0 | $0 | 6,206 | $49,468 | 0 | $0 |
| 2018-01 | 0 | $0 | 881,222 | $7,224,682 | 6,564 | $0 |
| 2017-12 | 0 | $0 | 17,117 | $159,667 | 0 | $0 |
| 2017-11 | 0 | $0 | 6,206 | $61,383 | 0 | $0 |
| 2017-07 | 0 | $0 | 24,260 | $290,046 | 13,823 | $35,248 |
| 2017-05 | 0 | $0 | 6,311 | $77,252 | 0 | $0 |
| 2017-03 | 166,666 | $1,999,992 | 0 | $0 | 0 | $0 |
| 2017-02 | 0 | $0 | 30,000 | $376,230 | 0 | $0 |
| 2016-12 | 0 | $0 | 45,000 | $763,530 | 0 | $0 |
| 2016-11 | 0 | $0 | 29,300 | $578,361 | 0 | $0 |
| 2016-09 | 0 | $0 | 61,000 | $1,222,057 | 14,000 | $104,580 |
| 2016-08 | 0 | $0 | 69,000 | $1,355,813 | 1,000 | $7,470 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-01-03 | Klimovsky Judith V | Option Ex | 60,414 | .00 | 0 |
| 2023-01-03 | Huber Reid M | Option Ex | 87,196 | .00 | 0 |
| 2023-01-03 | Daly James M | Option Ex | 60,414 | .00 | 0 |
| 2023-01-03 | Stonehouse Jon P | Option Ex | 121,452 | .00 | 0 |
| 2023-01-03 | Davis Stephen | Option Ex | 74,739 | .00 | 0 |
| 2022-09-01 | Klimovsky Judith V | Option Ex | 35,082 | .00 | 0 |
| 2022-09-01 | Huber Reid M | Option Ex | 46,489 | .00 | 0 |
| 2022-09-01 | Daly James M | Option Ex | 35,082 | .00 | 0 |
| 2022-09-01 | Stonehouse Jon P | Option Ex | 60,580 | .00 | 0 |
| 2022-09-01 | Davis Stephen | Option Ex | 43,400 | .00 | 0 |
| 2022-01-04 | Klimovsky Judith V | Option Ex | 14,602 | .00 | 0 |
| 2022-01-04 | Brown James F | Option Ex | 28,384 | .00 | 0 |
| 2022-01-04 | Huber Reid M | Option Ex | 19,494 | .00 | 0 |
| 2022-01-04 | Daly James M | Option Ex | 14,377 | .00 | 0 |
| 2022-01-04 | Stonehouse Jon P | Option Ex | 21,504 | .00 | 0 |
| 2022-01-04 | Davis Stephen | Option Ex | 18,715 | .00 | 0 |
| 2020-03-17 | Fair Richard A. (President and CEO) | Buy | 5,000 | 4.00 | 20,000 |
| 2020-01-03 | Foster Aaron E. (Sr VP, Head of Research) | Option Ex | 625 | .00 | 0 |
| 2020-01-03 | Williams Rosemary Y. (VP, Finance & PAO) | Option Ex | 781 | .00 | 0 |
| 2020-01-03 | Smith Alan K. (EVP, Technical Operations) | Option Ex | 1,563 | .00 | 0 |
| 2020-01-02 | Foster Aaron E. (Sr VP, Head of Research) | Option Ex | 2,500 | .00 | 0 |
| 2020-01-02 | Williams Rosemary Y. (VP, Finance & PAO) | Option Ex | 1,282 | .00 | 0 |
| 2020-01-02 | Smith Alan K. (EVP, Technical Operations) | Option Ex | 2,344 | .00 | 0 |
| 2019-11-13 | Woodard Jr Joseph Paul (SVP Clinical & Medical Affairs) | Option Ex | 3,750 | .00 | 0 |
| 2019-09-10 | Fair Richard A. (President and CEO) | Buy | 40,000 | 1.25 | 50,000 |
| 2019-08-29 | Ward Shane (Sr. VP and General Counsel) | Buy | 8,000 | 1.23 | 9,824 |
| 2019-08-21 | Fair Richard A. (President and CEO) | Buy | 20,000 | .99 | 19,780 |
| 2019-01-03 | Williams Rosemary Y. (Principal Accounting Officer) | Option Ex | 782 | .00 | 0 |
| 2019-01-03 | Smith Alan K. (EVP, Technical Operations) | Option Ex | 1,562 | .00 | 0 |
| 2019-01-03 | Spencer David M. (Chief Technology Officer) | Option Ex | 1,562 | .00 | 0 |
| 2019-01-02 | Williams Rosemary Y. (Principal Accounting Officer) | Option Ex | 1,281 | .00 | 0 |
| 2019-01-02 | Naeve Gregory S. (Chief Business Officer) | Option Ex | 2,031 | .00 | 0 |
| 2019-01-02 | Smith Alan K. (EVP, Technical Operations) | Option Ex | 2,344 | .00 | 0 |
| 2019-01-02 | Spencer David M. (Chief Technology Officer) | Option Ex | 2,500 | .00 | 0 |
| 2018-11-09 | Stonehouse Jon P | Buy | 10,000 | 4.56 | 45,599 |
| 2018-09-04 | Spencer David M. (Chief Technology Officer) | Sale | 10,000 | 7.04 | 70,410 |
| 2018-07-18 | Spencer David M. (Chief Technology Officer) | Sale | 40,000 | 7.63 | 305,120 |
| 2018-05-25 | Musso Alan A (CFO and Treasurer) | Sale | 6,206 | 7.97 | 49,468 |
| 2018-01-19 | Baker Julian (10% Owner) | Sale | 295,361 | 7.91 | 2,336,305 |
| 2018-01-18 | Baker Julian (10% Owner) | Sale | 324,774 | 8.12 | 2,635,865 |
| 2018-01-17 | Baker Julian (10% Owner) | Sale | 260,600 | 8.63 | 2,247,935 |
| 2018-01-09 | Smith Alan K. (EVP, Technical Operations) | Sale | 487 | 9.40 | 4,577 |
| 2018-01-03 | Smith Alan K. (EVP, Technical Operations) | Option Ex | 1,563 | .00 | 0 |
| 2018-01-03 | Spencer David M. (Chief Scientific Officer) | Option Ex | 1,563 | .00 | 0 |
| 2018-01-03 | Moseley Ken (Sr. VP and General Counsel) | Option Ex | 1,563 | .00 | 0 |
| 2018-01-03 | Musso Alan A (CFO and Treasurer) | Option Ex | 1,875 | .00 | 0 |
| 2017-12-11 | Musso Alan A (CFO and Treasurer) | Sale | 17,117 | 9.33 | 159,667 |
| 2017-11-27 | Musso Alan A (CFO and Treasurer) | Sale | 6,206 | 9.89 | 61,383 |
| 2017-07-24 | Smith Alan K. (EVP, Technical Operations) | Sale | 437 | 11.85 | 5,178 |
| 2017-07-13 | Moseley Ken (Sr. VP and General Counsel) | Sale | 13,823 | 12.26 | 169,469 |
| 2017-07-13 | Moseley Ken (Sr. VP and General Counsel) | Option Ex | 13,823 | 2.55 | 35,248 |
| 2017-07-10 | Spencer David M. (Chief Scientific Officer) | Sale | 10,000 | 11.54 | 115,399 |
| 2017-05-25 | Musso Alan A (CFO and Treasurer) | Sale | 6,311 | 12.24 | 77,252 |
| 2017-03-24 | Baker Bros. Advisors (gp) Llc (10% Owner) | Buy | 166,666 | 12.00 | 1,999,992 |
| 2017-02-07 | Slawin Kevin M. | Sale | 30,000 | 12.54 | 376,230 |
| 2016-12-15 | Slawin Kevin M. (Chief Technology Officer) | Sale | 30,000 | 15.45 | 463,530 |
| 2016-12-05 | Spencer David M. (Chief Scientific Officer) | Sale | 10,000 | 20.00 | 200,000 |
| 2016-11-28 | Musso Alan A (CFO and Treasurer) | Sale | 23,027 | 19.54 | 449,878 |
| 2016-11-25 | Musso Alan A (CFO and Treasurer) | Sale | 6,273 | 20.48 | 128,483 |
| 2016-09-23 | Spencer David M. (Chief Scientific Officer) | Sale | 6,200 | 20.19 | 125,171 |
| 2016-09-23 | Moseley Ken (Sr. VP and General Counsel) | Sale | 11,700 | 20.10 | 235,193 |
| 2016-09-23 | Moseley Ken (Sr. VP and General Counsel) | Option Ex | 11,700 | 7.47 | 87,399 |
| 2016-09-23 | Slawin Kevin M. (Chief Technology Officer) | Sale | 23,216 | 20.12 | 467,082 |
| 2016-09-22 | Spencer David M. (Chief Scientific Officer) | Sale | 10,000 | 19.68 | 196,830 |
| 2016-09-21 | Spencer David M. (Chief Scientific Officer) | Sale | 300 | 20.04 | 6,012 |
| 2016-09-21 | Moseley Ken (Sr. VP and General Counsel) | Sale | 100 | 20.04 | 2,004 |
| 2016-09-21 | Moseley Ken (Sr. VP and General Counsel) | Option Ex | 100 | 7.47 | 747 |
| 2016-09-21 | Slawin Kevin M. (Chief Technology Officer) | Sale | 200 | 20.04 | 4,008 |
| 2016-09-20 | Spencer David M. (Chief Scientific Officer) | Sale | 100 | 20.00 | 2,000 |
| 2016-09-20 | Moseley Ken (Sr. VP and General Counsel) | Sale | 200 | 20.00 | 4,000 |
| 2016-09-20 | Moseley Ken (Sr. VP and General Counsel) | Option Ex | 200 | 7.47 | 1,494 |
| 2016-09-20 | Slawin Kevin M. (Chief Technology Officer) | Sale | 400 | 20.00 | 8,000 |
| 2016-09-19 | Spencer David M. (Chief Scientific Officer) | Sale | 700 | 20.02 | 14,013 |
| 2016-09-19 | Moseley Ken (Sr. VP and General Counsel) | Sale | 1,300 | 20.01 | 26,018 |
| 2016-09-19 | Moseley Ken (Sr. VP and General Counsel) | Option Ex | 1,300 | 7.47 | 9,711 |
| 2016-09-19 | Slawin Kevin M. (Chief Technology Officer) | Sale | 2,606 | 20.01 | 52,151 |
| 2016-09-16 | Spencer David M. (Chief Scientific Officer) | Sale | 1,700 | 20.01 | 34,015 |
| 2016-09-16 | Moseley Ken (Sr. VP and General Counsel) | Sale | 700 | 20.00 | 14,000 |
| 2016-09-16 | Moseley Ken (Sr. VP and General Counsel) | Option Ex | 700 | 7.47 | 5,229 |
| 2016-09-16 | Slawin Kevin M. (Chief Technology Officer) | Sale | 1,578 | 20.00 | 31,560 |
| 2016-08-15 | Spencer David M. (Chief Scientific Officer) | Sale | 1,000 | 20.00 | 20,000 |
| 2016-08-15 | Moseley Ken (Sr. VP and General Counsel) | Sale | 1,000 | 20.00 | 20,000 |
| 2016-08-15 | Moseley Ken (Sr. VP and General Counsel) | Option Ex | 1,000 | 7.47 | 7,470 |
| 2016-08-15 | Slawin Kevin M. (Chief Technology Officer) | Sale | 67,000 | 19.64 | 1,315,813 |
| 2016-07-27 | Spencer David M. (Chief Scientific Officer) | Sale | 10,000 | 15.00 | 150,000 |
| 2016-07-27 | Slawin Kevin M. (Chief Technology Officer) | Sale | 15,000 | 15.00 | 225,000 |
| 2016-07-18 | Slawin Kevin M. (Chief Technology Officer) | Sale | 2,719 | 13.99 | 38,044 |
| 2016-07-15 | Slawin Kevin M. (Chief Technology Officer) | Sale | 22,281 | 13.72 | 305,673 |
| 2016-06-02 | Moseley Ken (Sr. VP and General Counsel) | Sale | 15,000 | 13.00 | 195,000 |
| 2016-06-02 | Moseley Ken (Sr. VP and General Counsel) | Option Ex | 15,000 | 2.55 | 38,250 |
| 2016-06-02 | Moseley Annemarie (COO/EVP Clinical Development) | Sale | 25,000 | 13.00 | 325,000 |
| 2016-06-02 | Moseley Annemarie (COO/EVP Clinical Development) | Option Ex | 25,000 | 2.55 | 63,749 |
| 2016-04-22 | Slawin Kevin M. (Chief Technology Officer) | Sale | 55,000 | 11.58 | 636,845 |
| 2016-01-04 | Moseley Annemarie (COO/EVP Clinical Development) | Sale | 35,000 | 19.48 | 681,905 |
| 2016-01-04 | Moseley Annemarie (COO/EVP Clinical Development) | Option Ex | 35,000 | 2.55 | 89,250 |
| 2015-12-14 | Spencer David M. (Chief Scientific Officer) | Option Ex | 5,000 | 2.55 | 12,750 |
| 2015-12-01 | Spencer David M. (Chief Scientific Officer) | Sale | 5,000 | 22.95 | 114,740 |
| 2015-11-24 | Musso Alan A (CFO and Treasurer) | Sale | 29,300 | 22.34 | 654,474 |
| 2015-11-16 | Slawin Kevin M. (Chief Technology Officer) | Sale | 24,000 | 20.65 | 495,504 |
| 2015-11-02 | Moseley Ken (Sr. VP and General Counsel) | Sale | 15,000 | 13.00 | 195,000 |
| 2015-11-02 | Moseley Ken (Sr. VP and General Counsel) | Option Ex | 15,000 | 2.55 | 38,250 |
| 2015-10-01 | Farrell Thomas J. (President and CEO) | Sale | 2,500 | 14.58 | 36,442 |
| 2015-09-21 | Spencer David M. (Chief Scientific Officer) | Option Ex | 5,000 | 2.55 | 12,750 |
| 2015-09-11 | Spencer David M. (Chief Scientific Officer) | Sale | 5,000 | 19.00 | 95,000 |
| 2015-09-01 | Farrell Thomas J. (President and CEO) | Sale | 2,500 | 16.78 | 41,942 |
| 2015-08-03 | Farrell Thomas J. (President and CEO) | Sale | 2,500 | 20.24 | 50,607 |
| 2015-07-15 | Slawin Kevin M. (Chief Technology Officer) | Sale | 6,000 | 20.00 | 120,000 |
| 2015-07-02 | Spencer David M. (Chief Scientific Officer) | Option Ex | 20,000 | 2.55 | 51,000 |
| 2015-07-01 | Moseley Ken (Sr. VP and General Counsel) | Sale | 15,000 | 20.96 | 314,415 |
| 2015-07-01 | Moseley Ken (Sr. VP and General Counsel) | Option Ex | 15,000 | 2.55 | 38,250 |
| 2015-07-01 | Moseley Annemarie (COO/EVP Clinical Development) | Sale | 35,000 | 20.96 | 733,635 |
| 2015-07-01 | Moseley Annemarie (COO/EVP Clinical Development) | Option Ex | 35,000 | 2.55 | 89,250 |
| 2015-06-16 | Spencer David M. (Chief Scientific Officer) | Sale | 20,000 | 23.31 | 466,160 |
Insider trading activities including stock purchases, stock sales, and option exercises of BLCM listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Bellicum Pharmaceuticals, Inc (symbol BLCM, CIK number 1358403) see the Securities and Exchange Commission (SEC) website.